← ANALYST RATINGS · TIPRANKS

Quanterix (QTRX): analyst forecast and price target

$2.87 −6.51% close 16.10.26 · market cap $145M · Healthcare · Medical - Devices IWM 0.01%
Price targets and ratings of

Analyst consensus

Hold

0 Buy2 Hold0 Sell

Ratings of 2 analysts in the last 3 months · top analysts only

12-month forecast

$3.25+13.2% upside

Based on 2 price targets given in the last 3 months, the average target is $3.25, the highest $3.50, the lowest $3.00. The average is +13.2% from the last price of $2.87.

$4.00$6.00$8.00Jan 26AprJulOctJan 27AprJulOctHigh$3.50Average$3.25Low$3.00
Highest target $3.50 Average target $3.25 Lowest target $3.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% TD Cowen $3.00 → $3.50+16.7% Hold +22.0% Reiterated 13.10.26on TipRanks 08:41 −0.3%next day −1.8%
Kyle Mikson CFA★★★★★★★★★★#2814 · hits 38% · avg +5.9% Canaccord Genuity $4.00 → $3.00−25.0% Hold +4.5% Reiterated 17.08.26on TipRanks 07:21 +13.2%next day −7.5% · 5 days −2.9%
Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% TD Cowen $4.00 → $3.00−25.0% Hold +4.5% Assigned 11.08.26on TipRanks 02:40 +8.8%next day +11.4% · 5 days +2.5%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Quanterix

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Anthropic Medical - Devices★★★★★★★★★★TipRanks - Anthropic · #3670
Hits 50%93 of 187 Average return +4.5%
1 year Anthropic Medical - Devices★★★★★★★★★★TipRanks - Anthropic · #3670
Hits 50%93 of 187 Average return +4.5%
2 years Anthropic Medical - Devices★★★★★★★★★★TipRanks - Anthropic · #3670
Hits 50%93 of 187 Average return +4.5%

Most profitable

3 months Anthropic Medical - Devices★★★★★★★★★★TipRanks - Anthropic · #3670
Hits 50%93 of 187 Average return +4.5%
1 year Anthropic Medical - Devices★★★★★★★★★★TipRanks - Anthropic · #3670
Hits 50%93 of 187 Average return +4.5%
2 years Anthropic Medical - Devices★★★★★★★★★★TipRanks - Anthropic · #3670
Hits 50%93 of 187 Average return +4.5%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $3.00 at a price of $3.71 (−19.1%); now: $3.25 at $2.87 (+13.2%).

$2.50$3.00$3.50Sep 15Oct 1Oct 15Top analysts$3.25Average target$3.25Price$2.87

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

024688Oct 255Nov5Dec5Jan 263Feb4Mar3Apr6May4Jun3Jul3Aug3Sep4Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy000000
Buy000000
Hold643334
Sell000000

Earnings and sales forecast

Next report: 10.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-0.42 (from $-0.48 to $-0.39). Last quarter: $-1.04.

Sales

Next quarter’s sales estimate — $34M (from $33M to $34M). Last quarter: $33M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Quanterix
  • CEO: Everett V. Cunningham
  • Employees: 450
  • Building 1, Billerica, MA, 01821, US
  • www.quanterix.com

Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.

Data from the stock’s TipRanks forecast page, read 154 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗